Year: 2019
Type: article
Abstract: Key Points Teriflunomide, the active metabolite of leflunomide, downregulates c-Myc expression through inhibition of PIM kinases. Leflunomide together with lenalidomide significantly extended survival in an in vivo MM model.
Source: Blood Advances
Authors: Ralf Buettner, Corey Morales, Enrico Caserta, Estelle Troadec, Emine G. Gunes, Domenico Viola, Jihane Khalife, Hongzhi Li, Jonathan J. Keats, Austin Christofferson, Xiwei Wu, Timothy W. Synold, Joycelynne Palmer, James F. Sanchez, Alexander Pozhitkov, Nagarajan Vaidehi, Guido Marcucci, Amrita Krishnan, Michael A. Rosenzweig, Flavia Pichiorri, Steven T. Rosen
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,800
Awards: G1923021002, G772794905, G9000092632
OpenAlex ID: W2929868087